Researchers at the NYU Pain Research Center have found a new receptor for nerve growth factor that plays an important role in pain signaling, even though it does not signal on its own, according to a study published in the Journal of Clinical Investigation.
Liquidia YUTREPIA inhalation powder gains FDA tentative approval
The Phase III INSPIRE trial served as the basis for the tentative approval. Credit: Sai Thaw Kyar/Shutterstock. Biopharmaceutical company Liquidia has received tentative approval from
August 20, 2024